Astra Wins MedImmune Auction; $15.6 Billion Price Tag Raises Eyebrows

AstraZeneca's move to bolster its biologics portfolio through the acquisition of MedImmune for roughly $15.6 billion illustrates the increasingly high stakes of mergers in the biotech space

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet